These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6122187)

  • 1. Effects of withdrawal from long-term barbital treatment on open-field behaviour and seizure susceptibility of rats.
    Palermo-Neto J; De Lima TC
    Neuropharmacology; 1982 Mar; 21(3):277-81. PubMed ID: 6122187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system supersensitivity and withdrawal from long-term treatment with barbital.
    Sandoval MR; Palermo-Neto J
    Neuropharmacology; 1985 Dec; 24(12):1247-51. PubMed ID: 4094660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased susceptibility of audiogenic rats to barbital withdrawal convulsions.
    Bourn WM; Garrett RL
    Pharmacol Biochem Behav; 1983 Nov; 19(5):839-41. PubMed ID: 6685882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Amino-7-phosphonoheptanoic acid, a selective antagonist of N-methyl-D-aspartate, prevents barbital withdrawal-induced convulsions and the elevation of cerebellar cyclic GMP in dependent rats.
    McCaslin PP; Morgan WW
    Neuropharmacology; 1987 Jul; 26(7A):731-5. PubMed ID: 2819762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticonvulsive activity of several excitatory amino acid antagonists against barbital withdrawal-induced spontaneous convulsions.
    McCaslin PP; Morgan WW
    Eur J Pharmacol; 1988 Mar; 147(3):381-6. PubMed ID: 3378564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of central monoamine compounds on tranylcypromine-induced barbital-withdrawal convulsions.
    Tagashira E; Hiramori T; Nakao K; Urano T; Yanaura S
    Life Sci; 1983 Apr; 32(14):1599-606. PubMed ID: 6682167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The open field: a simple method to show ethanol withdrawal symptoms.
    Capaz FR; Vanconcellos LE; De Moraes S; Neto JP
    Arch Int Pharmacodyn Ther; 1981 Jun; 251(2):228-36. PubMed ID: 7197142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of treatment duration on audiogenic seizure susceptibility during barbiturate withdrawal in rats.
    McGee DH; Bourn WM
    Experientia; 1978 Jul; 34(7):873-4. PubMed ID: 566673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced detection of hyperactivity after drug withdrawal with a simple modification of the open-field apparatus.
    Barros HM; Tannhauser MA; Tannhauser SL; Tannhauser M
    J Pharmacol Methods; 1991 Dec; 26(4):269-75. PubMed ID: 1758193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GABAergic influences on barbital withdrawal induced convulsions.
    Sandoval MR; Palermo-Neto J
    Gen Pharmacol; 1986; 17(4):431-5. PubMed ID: 3758649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participant of serotonin turnover rate in the brain on barbital withdrawal convulsion.
    Tagashira E; Hiramori T; Urano T; Nakao K; Yanaura S
    Jpn J Pharmacol; 1982 Feb; 32(1):159-67. PubMed ID: 6177889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased response of cerebellar cGMP to kainate but not NMDA or quisqualate following barbital withdrawal from dependent rats.
    McCaslin PP; Morgan WW
    Eur J Pharmacol; 1989 Dec; 173(2-3):127-32. PubMed ID: 2560429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on interactions between striatal dopaminergic and cholinergic mechanisms in the early abstinence after chronic treatment with barbital in the rat.
    Persson SA; Wahlström G
    Subst Alcohol Actions Misuse; 1984; 5(3):149-57. PubMed ID: 6438820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenoceptor supersensitivity in the isolated rat vas deferens during barbital withdrawal.
    Saban R; Capaz FR; De Moraes S
    Eur J Pharmacol; 1982 Aug; 82(1-2):37-45. PubMed ID: 6889970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of withdrawal from long-term diphenylhydantoin treatment on audiogenic and maximal electroshock-induced seizures in rats.
    De Lima TC; Palermo Neto J
    Acta Neurol Scand; 1981 Mar; 63(3):189-96. PubMed ID: 7211184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cortical and subcortical EEG patterns during moderate-intensity barbiturate withdrawal.
    Hinman DJ; Okamoto M
    Exp Neurol; 1984 Mar; 83(3):555-67. PubMed ID: 6538142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of alcohol and barbital physical dependence.
    Kaneto H; Kawatani S; Kaneda H
    Yakubutsu Seishin Kodo; 1986 Jun; 6(2):267-73. PubMed ID: 3776353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-substitution of diazepam for barbital results in only a low incidence of audiogenic seizures upon withdrawal in dependent rats.
    Reigel CE; Bourn WM
    Proc West Pharmacol Soc; 1994; 37():137-40. PubMed ID: 7984646
    [No Abstract]   [Full Text] [Related]  

  • 19. Repeated withdrawal from barbital as a drive for 'drug taking behavior' in rats.
    Jänicke UA; Coper H
    Drug Alcohol Depend; 1984 Jan; 13(1):43-54. PubMed ID: 6539666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical dependence produced by long duration, low dose chronic barbital treatment.
    Okamoto M; Hinman DJ
    Subst Alcohol Actions Misuse; 1984; 5(2):97-103. PubMed ID: 6540898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.